City

Nijmegen (2)

Ghent (1)

Kopenhagen (1)

Munchen (1)

Newcastle upon Tyne (1)

Overall Status

Recruiting (2)

Completed (1)

Phase

phase 2 (2)

phase 1 (1)

Sponsor

Khondrion BV (3)

Collaborator

Certara (2)

Julius Clinical (2)

ProPharma Group (2)

Ardena (1)

Drug Research Unit Ghent, Belgium (1)

Europees Fonds voor Regionale Ontwikkeling (EFRO) (1)

Intervention

placebo (2)

kh176 (1)

oral administration of 100 mg kh176 twice daily (1)

sonlicromanol (1)

Study Documents

Intervention Type

drug (3)

Funder Type

Industry (3)

Study Type

Interventional (3)

mitochondrial dna trnaleu(uur) m.3243a<g mutation

Showing 1 - 3 of 3

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation, Maternally Inherited Diabetes and Deafness (MIDD)

Recruiting

Mitochondrial Diseases
+4 more

Oral administration of 100 mg KH176 twice daily

Kopenhagen, Denmark
+3 more

Jun 24, 2022

Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation, MELAS Trial in Nijmegen (Sonlicromanol, Placebo)

Recruiting

Mitochondrial Diseases
+3 more

Sonlicromanol
Placebo

Nijmegen, Gelderland, Netherlands

Radboud University Medical Center

Jan 26, 2022

MELAS, LHON, Leigh Syndrome Trial in Ghent (KH176, )

Completed

Has Results

MELAS
+4 more

KH176
placebo

Ghent, Belgium

Drug Research Unit Ghent

Oct 15, 2021